Meeting
2018 Genitourinary Cancers Symposium
Is it the time to shift paradigms in castration naïve prostate cancer (CNPC): A meta-analysis of upfront docetaxel and abiraterone in men with CNPC.
Authors
Guangxi Sun
West China Hospital, Chengdu, China
Guangxi Sun , Xingming Zhang , Junru Chen , Banghua Liao , Jinge Zhao , Pengfei Shen , Hao Zeng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 360)
DOI
10.1200/JCO.2018.36.6_suppl.360
Abstract #
360
Poster Bd #
E7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2022 ASCO Genitourinary Cancers Symposium
Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).
First Author: Hirotsugu Uemura
Poster
2021 Genitourinary Cancers Symposium
Prescribing patterns in patients with metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Nataliya Mar